Specialist Updates 
Cardiology

SGLT2 inhibitor ‘shows similar efficacy’ for men and women with HFrEF

The results are from a prespecified analysis of the pivotal DAPA-HF study
Reuters Health
0
13 April 2021
Save
ClosePlease login
Breathless senior Asian woman

Dapagliflozin reduces the risk of worsening heart failure and death similarly in both sexes in patients with heart failure with reduced ejection fraction (HFrEF), researchers say.

And symptoms, function, and quality of life as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) improved to similar degrees in men and women, they report in JAMA Cardiology.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .